Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes

T1D Exchange Clinic Network

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

OBJECTIVE: It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment approaches and insurance coverage. The frequency of residual insulin secretion in a large cohort of individuals at varying ages of diagnosis and type 1 diabetes duration is unknown.

RESEARCH DESIGN AND METHODS: The frequency of residual insulin secretion was determined by measurement of nonfasting serum C-peptide concentration in 919 individuals with type 1 diabetes according to prespecified groups based on age at diagnosis and duration of disease (from 3 to 81 years' duration). Stimulated C-peptide was measured in those with detectable nonfasting values and a group of those with undetectable values as control.

RESULTS: The overall frequency of detectable nonfasting C-peptide was 29%, decreasing with time from diagnosis regardless of age at diagnosis. In all duration groups, the frequency of C-peptide was higher with diagnosis age >18 years compared with ≤18 years. Nineteen percent of those with undetectable nonfasting C-peptide were C-peptide positive upon stimulation testing.

CONCLUSIONS: The American Diabetes Association's definition of type 1 diabetes as "usually leading to absolute insulin deficiency" results in clinicians often considering the presence of residual insulin secretion as unexpected in this population. However, our data suggest that residual secretion is present in almost one out of three individuals 3 or more years from type 1 diabetes diagnosis. The frequency of residual C-peptide decreases with time from diagnosis regardless of age at diagnosis, yet at all durations of disease, diagnosis during adulthood is associated with greater frequency and higher values of C-peptide.

Original languageEnglish
Pages (from-to)476-481
Number of pages6
JournalDiabetes Care
Volume38
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

C-Peptide
Type 1 Diabetes Mellitus
Insulin
Insurance Coverage

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. / T1D Exchange Clinic Network.

In: Diabetes Care, Vol. 38, No. 3, 01.03.2015, p. 476-481.

Research output: Contribution to journalArticle

T1D Exchange Clinic Network. / Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. In: Diabetes Care. 2015 ; Vol. 38, No. 3. pp. 476-481.
@article{ddc1451045bf4179861222b49022bee2,
title = "Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes",
abstract = "OBJECTIVE: It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment approaches and insurance coverage. The frequency of residual insulin secretion in a large cohort of individuals at varying ages of diagnosis and type 1 diabetes duration is unknown.RESEARCH DESIGN AND METHODS: The frequency of residual insulin secretion was determined by measurement of nonfasting serum C-peptide concentration in 919 individuals with type 1 diabetes according to prespecified groups based on age at diagnosis and duration of disease (from 3 to 81 years' duration). Stimulated C-peptide was measured in those with detectable nonfasting values and a group of those with undetectable values as control.RESULTS: The overall frequency of detectable nonfasting C-peptide was 29{\%}, decreasing with time from diagnosis regardless of age at diagnosis. In all duration groups, the frequency of C-peptide was higher with diagnosis age >18 years compared with ≤18 years. Nineteen percent of those with undetectable nonfasting C-peptide were C-peptide positive upon stimulation testing.CONCLUSIONS: The American Diabetes Association's definition of type 1 diabetes as {"}usually leading to absolute insulin deficiency{"} results in clinicians often considering the presence of residual insulin secretion as unexpected in this population. However, our data suggest that residual secretion is present in almost one out of three individuals 3 or more years from type 1 diabetes diagnosis. The frequency of residual C-peptide decreases with time from diagnosis regardless of age at diagnosis, yet at all durations of disease, diagnosis during adulthood is associated with greater frequency and higher values of C-peptide.",
author = "{T1D Exchange Clinic Network} and Davis, {Asa K.} and DuBose, {Stephanie N.} and Haller, {Michael J.} and Miller, {Kellee M.} and Linda DiMeglio and Bethin, {Kathleen E.} and Goland, {Robin S.} and Greenberg, {Ellen M.} and Liljenquist, {David R.} and Ahmann, {Andrew J.} and Marcovina, {Santica M.} and Peters, {Anne L.} and Beck, {Roy W.} and Greenbaum, {Carla J.}",
year = "2015",
month = "3",
day = "1",
doi = "10.2337/dc14-1952",
language = "English",
volume = "38",
pages = "476--481",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes

AU - T1D Exchange Clinic Network

AU - Davis, Asa K.

AU - DuBose, Stephanie N.

AU - Haller, Michael J.

AU - Miller, Kellee M.

AU - DiMeglio, Linda

AU - Bethin, Kathleen E.

AU - Goland, Robin S.

AU - Greenberg, Ellen M.

AU - Liljenquist, David R.

AU - Ahmann, Andrew J.

AU - Marcovina, Santica M.

AU - Peters, Anne L.

AU - Beck, Roy W.

AU - Greenbaum, Carla J.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - OBJECTIVE: It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment approaches and insurance coverage. The frequency of residual insulin secretion in a large cohort of individuals at varying ages of diagnosis and type 1 diabetes duration is unknown.RESEARCH DESIGN AND METHODS: The frequency of residual insulin secretion was determined by measurement of nonfasting serum C-peptide concentration in 919 individuals with type 1 diabetes according to prespecified groups based on age at diagnosis and duration of disease (from 3 to 81 years' duration). Stimulated C-peptide was measured in those with detectable nonfasting values and a group of those with undetectable values as control.RESULTS: The overall frequency of detectable nonfasting C-peptide was 29%, decreasing with time from diagnosis regardless of age at diagnosis. In all duration groups, the frequency of C-peptide was higher with diagnosis age >18 years compared with ≤18 years. Nineteen percent of those with undetectable nonfasting C-peptide were C-peptide positive upon stimulation testing.CONCLUSIONS: The American Diabetes Association's definition of type 1 diabetes as "usually leading to absolute insulin deficiency" results in clinicians often considering the presence of residual insulin secretion as unexpected in this population. However, our data suggest that residual secretion is present in almost one out of three individuals 3 or more years from type 1 diabetes diagnosis. The frequency of residual C-peptide decreases with time from diagnosis regardless of age at diagnosis, yet at all durations of disease, diagnosis during adulthood is associated with greater frequency and higher values of C-peptide.

AB - OBJECTIVE: It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment approaches and insurance coverage. The frequency of residual insulin secretion in a large cohort of individuals at varying ages of diagnosis and type 1 diabetes duration is unknown.RESEARCH DESIGN AND METHODS: The frequency of residual insulin secretion was determined by measurement of nonfasting serum C-peptide concentration in 919 individuals with type 1 diabetes according to prespecified groups based on age at diagnosis and duration of disease (from 3 to 81 years' duration). Stimulated C-peptide was measured in those with detectable nonfasting values and a group of those with undetectable values as control.RESULTS: The overall frequency of detectable nonfasting C-peptide was 29%, decreasing with time from diagnosis regardless of age at diagnosis. In all duration groups, the frequency of C-peptide was higher with diagnosis age >18 years compared with ≤18 years. Nineteen percent of those with undetectable nonfasting C-peptide were C-peptide positive upon stimulation testing.CONCLUSIONS: The American Diabetes Association's definition of type 1 diabetes as "usually leading to absolute insulin deficiency" results in clinicians often considering the presence of residual insulin secretion as unexpected in this population. However, our data suggest that residual secretion is present in almost one out of three individuals 3 or more years from type 1 diabetes diagnosis. The frequency of residual C-peptide decreases with time from diagnosis regardless of age at diagnosis, yet at all durations of disease, diagnosis during adulthood is associated with greater frequency and higher values of C-peptide.

UR - http://www.scopus.com/inward/record.url?scp=84930760699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930760699&partnerID=8YFLogxK

U2 - 10.2337/dc14-1952

DO - 10.2337/dc14-1952

M3 - Article

VL - 38

SP - 476

EP - 481

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -